Novavax’s Nuvaxovid Receives Expanded Authorization for COVID-19 in Canada
- Nuvaxovid (NVX-CoV2373) received expanded authorization from Health Canada as a homologous booster for active immunization to prevent COVID-19 in adults aged ≥18yrs.
- The expanded authorization was based on the P-II trial in South Africa & P-III (Prevent-19) trial in the US & Mexico evaluating NVX-CoV2373 in healthy adult participants aged 6-11mos., following their initial 2-dose regimen in the trials. The results from P-III trials showed a greater immune response to levels in line with or over those linked to protection
- Local & systemic reactions had a median duration of ~2 Days, the incidence of grade ≥3 events were low, and reactogenicity events showed an increased incidence across 3 doses of Nuvaxovid with increased immunogenicity
Ref: PRNewswire | Image: Novavax
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.